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production yield, while 5MeW-containing variants showed 
the lowest yield. The dehydration efficiency of serines or 
threonines was affected by the tryptophan mutants of I4W 
and V32W. The affinity of the peptides for the cation-ion 
exchange and reverse phase chromatography columns 
was significantly reduced when 5HW was incorporated. 
The antimicrobial activity of IIW and its 5FW analogue 
both decreased two times compared to that of nisin, while 
that of its 5HW analogue decreased four times. The 5FW 
analogue of I4W also showed two times decreased activ-
ity than nisin. However, the mutant M17W and its 5HW 
analogue both showed 32 times reduced activity relative to 
that of nisin.
Keywords Lantibiotics · Nisin · Tryptophan analogues · 
Biosynthetic incorporation · Non-canonical amino acids
Introduction
As the traditional antibiotics are not sufficient to deal with 
several drug-resistant pathogens (Ferri et al. 2015), many 
efforts have been made in mining new antimicrobial agents 
and engineering pre-existing antimicrobial peptides. Lan-
tibiotics are gene-encoded and ribosomally synthesized 
peptides. After synthesis, they undergo various kinds of 
modifications conducted by enzymatic catalysis (Willey 
and van der Donk 2007). Lantibiotics are active mainly 
against Gram-positive bacteria (Bierbaum and Sahl 2009) 
and have been considered to possess pharmaceutical value 
in the future (Dischinger et al. 2014). The bioengineering 
of lantibiotics has been performed with various methods, 
including point mutation, modular shuttling, introducing 
new modifications and non-natural amino acids incorpora-
tion (Montalbán-López et al. 2012).
Abstract Lantibiotics are posttranslationally modified 
peptides with efficient inhibitory activity against various 
Gram-positive bacteria. In addition to the original modi-
fications, incorporation of non-canonical amino acids can 
render new properties and functions to lantibiotics. Nisin 
is the most studied lantibiotic and contains no tryptophan 
residues. In this study, a system was constructed to incor-
porate tryptophan analogues into nisin, which included the 
modification machinery (NisBTC) and the overexpression 
of tryptophanyl-tRNA synthetase (TrpRS). Tryptophan 
and three different tryptophan analogues (5-fluoroTrp 
(5FW), 5-hydroxyTrp (5HW) and 5-methylTrp (5MeW)) 
were successfully incorporated at four different posi-
tions of nisin (I1W, I4W, M17W and V32W). The incor-
poration efficiency of tryptophan analogues into mutants 
I1W, M17W and V32W was over 97 %, while the mutant 
I4W showed relatively low incorporation efficiency (69–
93 %). The variants with 5FW showed relatively higher 
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Nisin (Fig. 1b) is the first described lantibiotic and is 
produced by Lactococcus lactis (Rogers 1928). The biosyn-
thesis of nisin (Lubelski et al. 2008) starts from a ribosomal 
synthesis of the prepeptide encoded by the nisA gene. The 
prepeptide consists of a leader part and a core peptide part. 
The leader part will guide the prepeptide to NisB which 
will catalyse the dehydration of serines or threonines in the 
core peptide part to dehydroalanines (Dha) or dehydrobu-
tyrines (Dhb) by glutamyl-tRNAGlu-involved glutamylation 
and glutamate elimination (Ortega et al. 2015). The Dha or 
Dhb is then coupled to cysteine by a sulfhydryl addition 
reaction catalysed by NisC (Kuipers et al. 1993a; Koponen 
et al. 2002). NisB and NisC work interactively and direc-
tionally (Lubelski et al. 2009). The modified prenisin is 
transported outside the cell by an ABC transporter NisT 
(Qiao and Saris 1996; Kuipers et al. 2004).
Nisin can efficiently inhibit the growth of Gram-positive 
bacteria by two kinds of inhibition mechanisms. The first 
two rings of nisin can bind to lipid II which is essential 
for cell wall synthesis. The C-terminus of nisin can insert 
into the membrane enabling pore formation (Breukink and 
de Kruijff 2006). Mutagenesis of nisin has been conducted 
extensively and several residues have been mutated to tryp-
tophan, e.g. I1W, M17W and V32W, which all reduce nisin 
activity but not dramatically, against Micrococcus flavus by 
two to three times and against Streptococcus thermophilus 
by three to eight times (Kuipers et al. 1995; Demel et al. 
1996; Van Kraaij et al. 1997; Breukink et al. 1998).
In vivo incorporation of non-canonical amino acids 
(ncAAs) into proteins has been conducted in two ways 
(Hoesl and Budisa 2011). One is called “genetic code 
expansion” which means that non-canonical amino acids 
are inserted by suppressor tRNAs into the position where 
a termination codon exists. The other one is “genetic code 
engineering” which means canonical amino acids are 
replaced by their non-canonical analogues (i.e. ncAAs) 
during translation in an auxotrophic strain. Previously, 
Met, Trp and Pro analogues have been incorporated into 
a two-component lantibiotic lichenicidin using related 
auxotrophic E. coli strains (Oldach et al. 2012). Addi-
tionally, several kinds of lacticin 481 mutants containing 
ncAAs have been generated by in vitro mutasynthesis, 
i.e. the chemically synthesized substrate peptides contain-
ing ncAAs were modified by the enzyme LctM in vitro. 
Two of these lacticin 481 mutants containing Trp19Nal 
(Nal = naphthylalanine) or Phe23hPhe (hPhe = homophe-
nylalanine) showed enhanced activity against L. lactis HP 
(Levengood et al. 2009).
Fig. 1  a Structures of tryptophan and its analogues used in this 
study. 5FW, 5-fluorotryptophan; 5HW, 5-hydroxytryptophan; 5MeW, 
5-methyltryptophan. b Incorporation of tryptophan analogues into 
nisin A. Dha, dehydroalanine; Dhb, dehydrobutyrine; Ala-S-Ala, lan-
thionine; Abu-S-Ala, methyllanthionine. Ile1, Ile4, Met17 and Val32 
(green label) were mutated and replaced by Trp or Trp analogues (red 
label). The colour depth of the red label indicates the yield of the var-
iant and darker colour means higher yield. The antimicrobial activity 
of some variants compared to wild-type nisin is indicated. The yield 
of other variants was too low to purify enough material for accurate 
minimum inhibitory concentration (MIC) determination. In general, 
incorporation of a Trp analogue in nisin gave lower production yields 
and equal or higher MIC values than natural Trp incorporation
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Here, we investigate the in vivo incorporation of tryp-
tophan analogues into nisin, as this could yield improved 
or altered-specificity variants. Previously, an efficient tryp-
tophan analogue incorporation system for Lactococcus 
lactis has been reported (Petrović et al. 2013). In the L. 
lactis tryptophan auxotroph strain (PA1002), a native tryp-
tophanyl-tRNA synthetase (lacTrpRS) was overexpressed. 
This TrpRS has a relaxed substrate specificity, which can 
increase the incorporation efficiency of Trp analogues and 
also improve the yield of the target protein. This system 
was combined with a system to incorporate lanthionine 
bridges based on the nisin modification machinery. We 
used one new (I4) and three previously published posi-
tions (1, 17 and 32) for the Trp codons. The latter ones have 
slightly higher MIC values than wild-type nisin.
In this research, three kinds of common tryptophan ana-
logues (Fig. 1a) were successfully incorporated into nisin. 
The incorporation efficiency of Trp analogues was analysed 
with LC–MS. The new properties and antimicrobial activi-
ties of the variants are described.
Materials and methods
Bacterial strains and growth conditions
The bacterial strains used in this study are listed in Table 1. 
L. lactis strains were cultured in M17 broth supplemented 
with 0.5 % (w/v) glucose (GM17) or GM17 agar for 
genetic manipulation or in minimal expression medium 
(MEM) for protein expression at 30 °C (Rink et al. 2005a). 
Minimal chemical defined medium (mCDM) was spe-
cially used for protein expression and tryptophan analogue 
incorporation.
Genetic manipulation
The plasmid pCZnisA–trpRS was constructed by ligat-
ing the gene trpRS behind the nisA gene. The gene trpRS 
including the ribosomal binding site (RBS) and a termina-
tor was cloned from the plasmid pMG36e–trpRS by per-
forming round PCR (Zhou et al. 2015) with two primers 
containing BamHI and XhoI cleavage sites, respectively. 
The pCZnisA fragment was obtained by performing PCR 
with the reverse primer containing a BamHI cleavage site 
which binds to the sequence right behind the nisA gene. 
The forward primer was designed to amplify the full-length 
plasmid. The XhoI cleavage site is originally behind the 
terminator of nisA gene. Both PCR products were cut with 
BamHI and XhoI, and the digested products were purified 
(Roche Switzerland) and ligated with T4 ligase (Thermo 
Scientific). The ligation product was transformed into 
NZ9000 as described previously (Holo and Nes 1995). 
All the point mutants were made by round PCR using 
pCZnisA–trpRS as a template. For tryptophan analogue 
incorporation, the constructed plasmids pCZnisA–trpRS 
Table 1  Strains and plasmids used in this study
a EryR Erythromycin resistance
b CmR Chloramphenicol resistance
Strains or plasmids Characteristics Reference
Strain
 Lactococcus lactis NZ9000 pepN::nisRK Kuipers et al. (1997)
 L. lactis PA1001 Derivative of NZ9000, lacking acmA and htrA Bosma et al. (2006)
 L. lactis PA1002 Derivative of PA1001, lacking trpB and trpA El Khattabi et al. (2008)
Plasmids
 pIL3EryBTC nisBTC, encoding nisin modification machinery, EryRa van Heel et al. (2013)
 pCZ–nisA nisA, encoding NisA, under the control of PczcD promoter, CmRb Mu et al. (2013)
 pMG36e–trpRS trpRS, encoding tryptophanyl-tRNA synthetase (TrpRS), under the control of P32  
promoter, EryRa
Petrović et al. (2013)
 pCZnisA–trpRS nisA and trpRS, encoding NisA and TrpRS, under the control of PczcD promoter, CmRb This study
 pCZnisA(I1W)–trpRS Point mutant of pCZnisA–trpRS, with the Ile 1 of nisin changed to Trp This study
 pCZnisA(I4W)–trpRS Point mutant of pCZnisA–trpRS, with the Ile 4 of nisin changed to Trp This study
 pCZnisA(M17W)–trpRS Point mutant of pCZnisA–trpRS, with the Met 17 of nisin changed to Trp This study
 pCZnisA(V32W)–trpRS Point mutant of pCZnisA–trpRS, with the Val 32 of nisin changed to Trp This study
 pNZnisP8H nisP, encoding NisP mutant, with 8 histidines, CmRb Unpublished data
Indicator strain
 Lactococcus lactis MG1363 Indicator strain Gasson (1983)
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with or without mutants were transformed into PA1002-
containing plasmid pIL3EryBTC.
Incorporation of tryptophan analogues into nisin
The biosynthetic incorporation of Trp analogues is accord-
ing to the paper of Petrović et al. (Petrović et al. 2013). 
The expression strain PA1002 harbouring the pIL3EryBTC 
plasmid and a pCZnisA–trpRS plasmid (Table 1) was cul-
tured overnight in 5 ml M17 broth with 0.5 % (w/v) glu-
cose, 5 µg/ml erythromycin and 5 µg/ml chlorampheni-
col at 30 °C. The overnight culture was then inoculated to 
the same medium (100 ml) and incubated at 30 °C. When 
OD600 reached 0.4–0.5, 2 nM nisin was added to induce 
the expression of NisBTC. After 3 h induction, cells were 
harvested by centrifugation at 5400g for 10 min. Subse-
quently, cells were washed with PBS three times and resus-
pended in 100 ml mCDM medium without tryptophan and 
with 3 µg/ml erythromycin, 3 µg/ml chloramphenicol and 
0.2 nM nisin. After starvation at 30 °C for 30 min, 1 mM 
Trp analogues (5-methyl-tryptophan, 5-fluoro-tryptophan or 
5-hydroxy-tryptophan) and 1 mM ZnSO4 were added. The 
culture was incubated at 30 °C overnight to express the nisin 
peptides. The supernatant was harvested by centrifugation at 
9000 rpm during 10 min at room temperature or 4 °C. To 
remove the leader of the peptides before purification, the 
strain NZ9000 pNZnisPhis was fermented first with GM17 
containing 5 µg/ml chloramphenicol until OD600 reached 
0.7, and then the cells were harvested and resuspended in 
MEM with 0.5 % (w/v) glucose and 3 µg/ml chlorampheni-
col and induced with 2 nM nisin for 3 h. The supernatant 
was harvested by centrifugation (9000 rpm, 10 min).
LC–MS of nisin variants with Trp or Trp analogues
4 ml supernatant was first concentrated by TCA precipi-
tation (Link and LaBaer 2011) and then dissolved with 
100 μl 0.01 % acetic acid. The concentrated peptides were 
analysed by FTMS using a Shimadzu UFLC system (Shi-
madzu, Den Bosch, The Netherlands) coupled online via 
the HESI interface with an LTC-Orbitrap-XL mass spec-
trometer (Thermo Fisher Scientific., San Jose, CA). 5 μl 
of the diluted samples was loaded onto a Shimpack XR-
ODS2 column (2.0 × 50 mm, 2.2 μm particles). The fol-
lowing mobile phase gradient was delivered at a flow rate 
of 0.2 ml/min: 10 % B 1 min hold; linear gradient 10–35 % 
B in 19 min; 35–90 % B in 0.1 min; hold 90 % B 4.9 min. 
Solvent A was H2O (v/v) with 0.1 % formic acid and sol-
vent B was 50:50 IPA/acetonitrile (v/v) with 0.1 % formic 
acid. Typical spray voltage was 3.5 kV [heater 250 °C, 
sheath gas flow 35 and auxiliary gas flow 10 (arbitrary 
units)]; ion transfer tube temperature was 300 °C. Analy-
sis consisted of a high-resolution scan from m/z 350 to m/z 
1800 with target mass resolution of 100,000 (FWHM, full 
width at half maximum at m/z 400). The obtained data were 
processed using the Thermo Xcalibur Xtract algorithm for 
deconvoluting isotopically resolved mass spectra.
Purification and quantification of nisin variants 
with Trp or Trp analogues
To obtain pure peptides for activity tests, the supernatant of 
100 ml culture (filtered with 0.2 µm filter, Millipore) was 
first incubated with 5 ml supernatant of NisP (filtered) at 
30 °C for 1 h to cut off the leader part and then purified 
with cation-ion exchange (HiTrap SP FF, GE healthcare) 
(van Heel et al. 2013). The elutions were further loaded on 
a C18 column (Spherical C18, Sigma- Aldrich). The col-
umn was washed and eluted with different concentrations 
of solution B (solution A, milliQ with 0.1 % TFA; solution 
B, isopropanol: acetonitrile (2:1) with 0.1 % TFA). The 
elutions which were active against L. lactis were freeze-
dried and further purified with HPLC as described previ-
ously (Zhou et al. 2015). The fractions containing the peaks 
in the HPLC chromatogram were analysed by activity tests 
and MALDI-TOF (van Heel et al. 2013). The peak which 
was active and contained the pure peptide with right mass 
was freeze-dried and quantified with HPLC as described 
previously (Zhou et al. 2015).
Activity tests
The indicator strain L. lactis MG1363 was first streaked on 
a GM17 plate and cultured overnight. Before testing the 
MIC, three to five colonies were picked and cultured with 
GM17 medium until OD600 reached 0.5. The culture was 
diluted 500 times with GM17 and mixed with the same vol-
ume of peptides dissolved in GM17. The MIC value test 
was performed according to Wiegand et al. (2008).
Results
A new expression system to incorporate tryptophan 
analogues into nisin
As nisin is a ribosomally synthesized and posttranslation-
ally modified peptide, the expression and transportation 
of nisin need nisABTC gene expression. In the conven-
tional nisin production system, both nisA and nisBTC gene 
were controlled by the Pnis promoter in separate plasmids 
pNZnisA and pIL3EryBTC (Rink et al. 2005b; van Heel 
et al. 2013). However, in this research, we wanted to con-
trol the expression of the modification enzymes separately 
from the expression of nisin, to limit the incorporation of 
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tryptophan analogues into the modification machinery. As 
a second inducible promoter, we used zirex which is a tight 
and efficient zinc-inducible expression system for L. lactis. 
It contains a pneumococcal repressor SczA and PczcD (Mu 
et al. 2013). In the new system, the PczcD promoter was used 
to control the expression of nisin and its derivatives. In the 
system constructed by Petrović et al. (2013), the lacTrpRS 
protein was overexpressed and shown to be important for 
the incorporation. To incorporate tryptophan analogues into 
nisin more efficiently, lacTrpRS needs to be overexpressed. 
Previously, the trpRS gene is controlled by a constitutive 
promoter P32 in a separate plasmid pMG36e–trpRS. To 
avoid the need for three plasmids in one strain, the trpRS 
gene was cloned to plasmid pCZ–nisA, right behind the 
nisA gene and controlled by the PczcD promoter (Fig. 2) 
as well. So in this new system, the expression of NisBTC 
is controlled by Pnis and could be conducted prior to the 
expression of NisA variants. The TrpRS and NisA variants 
were expressed at the same time, which can increase the 
incorporation rate.
The variants were produced in different amounts, 
and are affected by the type of Trp analogues
The nisin gene does not encode any tryptophan residue 
naturally. Therefore, nisin was engineered to encode trypto-
phan residues at four different positions (I1W, I4W, M17W 
and V32W (Fig. 1). These mutants were used to evaluate 
the incorporation efficiency of the tryptophan analogues at 
the different positions. With the new incorporation system, 
tryptophan and three different tryptophan analogues (5FW, 
5HW or 5MeW) were incorporated into nisin. Figure 3 
shows the expression level of wild-type nisin and four sin-
gle-Trp-containing mutants of nisin cultured in the presence 
of Trp, 5FW, 5HW or 5MeW. The protein amount in the first 
four lanes showed that the wild-type nisin was expressed 
at a high level when tryptophan was in the medium, but in 
the presence of Trp analogues a lower production yield was 
observed. Especially when 5MeW was in the media, the 
production level was extremely low. The production level 
of all four nisin mutants showed almost the same trend as 
wild type, but mutant V32W showed much lower produc-
tion level than wild type and the three other mutants.
The variants were correctly modified and the Trp 
analogues were incorporated
As the TCA-precipitated prepeptides from supernatant con-
tain various kinds of peptides secreted by the cells, they 
Fig. 2  Map of the plasmid pCZnisA–trpRS. sczA, encoding the 
repressor of PczcD; PczcD, a zinc-inducible promoter; nisA, encoding 
NisA; trpRS, encoding tryptophanyl-tRNA synthetase; T, terminator; 
BamHI and XhoI, restriction sites; repA and repC, encoding plasmid 
replication proteins; cmR, chloramphenicol resistance gene. Partly 
referred to (Mu et al. 2013)
Fig. 3  Coomassie blue-stained tricine SDS-PAGE gel. Each well contained TCA-precipitated prepeptides from 600 μl supernatant. M1: protein 
marker (Biolabs); WT: wild type; Trp: tryptophan; F: 5-fluoroTrp; OH: 5-hydroxyTrp; Me: 5-methylTrp
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were used as samples for LC–MS analysis. The first Met is 
normally removed in the mature product of prenisin (Kui-
pers et al. 1993b) by a methionine aminopeptidase (MAP) 
(Sherman et al. 1985). However, a large portion of prepep-
tides produced by this system contained an N-terminal Met. 
As the peptides with or without Met1 showed almost the 
same ratio between peaks of different modifications, only 
the peaks without Met1 are shown in Table 2.
The incorporation efficiency indicates the ratio between 
the amount of peptides with tryptophan analogues and 
the total amount of peptides. The LC–MS data show that 
the incorporation efficiency of tryptophan analogues into 
mutants I1W, M17W and V32W was more than 97 %, as 
the peaks of peptides containing Trp were almost unde-
tectable. But in the case of I4W, a significant Trp variant 
peak was shown, and the incorporation efficiency was 
89 % for 5FW, 93 % for 5HW and 69 % for 5MeW. Nisin 
is normally dehydrated eight times, but seven or six times 
dehydration could also be observed. More than 70 % of 
the mutants I1W and M17W were dehydrated eight times, 
which is similar to the dehydration extent of nisin. How-
ever, the dehydration of I4W and V32W was dramatically 
affected by the mutation of Trp. 93 % of the I4-W variant 
was dehydrated seven times, while when Trp analogues 
were incorporated the eight times dehydrated peptides 
occupied a larger proportion. In the case of V32W, 60 % 
(Trp) or 69 % (5FW) of the products were dehydrated 
seven times. Furthermore, as there are two Met residues in 
nisin, oxidation of Met happens in a fraction of the prod-
uct. About 24–44 % of the products of I4W were oxidized. 
I4-5HW was oxidized two times in 20 % of the product. 
In the case of M17W incorporated with 5HW, about 65 % 
Table 2  The molecular mass of the nisin mutants after tryptophan analogues are incorporated
a  The values between brackets refer to the percentage of different variants; similarly hereinafter
b  ND Not detected
Mutants Modifications Predicted mass (Da) Observed mass (Da) of main peaks at different culture conditions
Trp 5FW 5HW 5MeW
I1W −8H2O 5757.750 5757.747
+F −8H2O 5775.741 5775.752
+OH −8H2O 5773.745 5773.737
+Me −8H2O 5771.766 5771.752
I4W −8H2O 5757.750 5757.735 (7)a 5757.776 (9) 5757.795 (2) 5757.789 (30)
−7H2O 5775.761 5775.724 (69)
−7H2O + Oxi 5791.756 5791.726 (24)
+F −8H2O 5775.741 5775.734 (59)
+F −8H2O + Oxi 5791.736 5791.733 (30)
+OH −8H2O 5773.745 5773.766 (35)
+OH −7H2O 5791.756 5791.753 (14)
+OH −8H2O + Oxi 5789.740 5789.751 (24)
+OH −8H2O + 2Oxi 5807.751 5807.743 (20)
+Me −8H2O 5771.766 5771.758 (33)
+Me −7H2O 5789.776 5789.765 (36)
M17W −8H2O 5739.794 5739.763
+F −8H2O 5757.784 5757.791
+OH −8H2O 5755.794 5755.727 (30)
+OH −8H2O + Oxi 5771.789 5771.751 (65)
+Me −8H2O 5753.809 5753.749
V32W −8H2O 5771.766 5771.757 (30)
−7H2O 5789.776 5789.768 (60)
+F −8H2O 5789.756 5789.752 (14)
+F −7H2O 5807.767 5807.759 (36)
+F −8H2O + Oxi 5805.751 5805.754 (8)
+F −7H2O + Oxi 5823.762 5823.756 (33)
+OH −8H2O 5787.761 NDb
+Me −8H2O 5785.781 NDb
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of the product was oxidized. When 5FW was incorporated 
into the mutant V32W, about 40 % of the peptides were 
oxidized. V32-5HW and V32-5MeW were not analysed 
because of the low production level.
The tryptophan analogues change the properties 
of nisin
Nisin is a positively charged and hydrophobic molecule. 
However, when introducing Trp or Trp analogues to it, 
nisin showed modified biochemical properties. This dif-
ference was reflected by the elution time of the peptides 
in cation-ion exchange and reverse phase chromatography 
(HPLC). The variants with 5HW were eluted about half 
column volume earlier than other variants during cation-
ion exchange (data not shown). The variants with Trp, 5FW 
or 5MeW showed slightly different elution time from nisin 
in HPLC. But the 5HW-containing variants showed much 
shorter retention time than other variants (Table 3).
Antimicrobial activity of the variants containing 
tryptophan analogues
Because of shortage of material, part of the tryptophan ana-
logues containing variants were purified (Fig. 4) and their 
antimicrobial activity was tested against L. lactis (Table 4). 
The results showed that the mutant I1W displayed only two 
times reduced activity than nisin, and incorporating 5FW 
analogue into this mutant did not change the activity. But 
the 5HW analogue of I1W displayed two times lower activ-
ity than I1W. As fully dehydrated I4W variant was difficult 
to obtain, the activity of I4W was not tested. The mutant I4W 
with 5FW incorporated contained 30 % oxidized variants and 
the peptides showed two times reduced activity compared to 
nisin. However, the M17W mutant and its 5HW incorporated 
variants displayed dramatically decreased (32 times) activity.
Discussion
Incorporation of non-canonical amino acids into natural 
products can be a strategy to improve the diverse properties 
of these compounds. For this purpose, an in vivo nisin—
tryptophan analogue incorporation system in L. lactis was 
created. Three different tryptophan analogues have been 
successfully incorporated at four different positions of 
nisin. In contrast to the in vitro incorporation (Levengood 
et al. 2009) and the in vivo incorporation system in E. 
coli (Hoesl and Budisa 2011), this is the first system con-
structed in L. lactis to incorporate unnatural amino acids 
into lantibiotics in vivo.
The newly constructed lanthionine and tryptophan ana-
logue incorporation system has several advantages. The 
combination of the zirex and the nisin-controlled gene 
expression system (NICE) allows for differential timing 
of the expression of the lantibiotic and its modification 
enzymes. Figure 5 shows three different nisin variants pro-
duction and tryptophan analogue incorporation systems. 
The enzymes NisBTC contain 17 Trp residues, and in 
the system presented in this work they were expressed in 
advance, which can avoid the Trp analogues being incorpo-
rated into NisBTC. This can thus accumulate large amount 
of modification enzymes before the expression of prenisin 
Table 3  Retention time of the nisin variants in HPLC













Fig. 4  Purified tryptophan analogues-containing variants shown by 
Coomassie blue-stained tricine SDS-PAGE gel
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variants. The TrpRS, a tryptophan-less protein, was over-
expressed together with prenisin, which is different from 
the original system for tryptophan analogue incorporation 
where the TrpRS was controlled by a constitutive promoter 
P32.
Both wild-type nisin and the mutants showed good 
production levels when tryptophan was used to culture 
the cells. This indicates that the new system works effi-
ciently in the production and modification of nisin vari-
ants. However, the expression levels were reduced dra-
matically when the tryptophan analogues were in the 
medium. This is probably because the tryptophan ana-
logues are toxic to the cells. If the tryptophan analogues 
were incorporated into NisBTC, the function of NisBTC 
Table 4  Antimicrobial activity of the tryptophan analogues-containing variants
a The MIC tests were repeated three times
Nisin variants Predicted mass (Da) Observed mass(Da) Modifications MIC against L. lactis MG1363 (nM)a
nisin 3352.5 3352.5 −8H2O 64
I1-W 3425.5 3425.6 −8H2O 128
I1-5FW 3443.5 3443.5 −8H2O 128
I1-5HW 3441.5 3441.5 −8H2O 256
I4-5FW 3443.5 3443.5 −8H2O (70 %) 128
3459.5 3459.5 −8H2O + Oxi (30 %)
M17-W 3407.6 3407.6 −8H2O 2048
M17-5HW 3423.6 3423.6 −8H2O 2048
Fig. 5  Nisin variant production and tryptophan analogue incorpora-
tion systems. Olive line the conventional NICE system; aqua line the 
tryptophan analogues incorporation system constructed by Petrović 
et al.; blue line the new system constructed in this research, which 
combines the NICE system, zirex system and the tryptophan ana-
logues incorporation system
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could be affected and the production level could be 
reduced.
The incorporation efficiency of three kinds of Trp ana-
logues into mutants I1W, M17W and V32W was over 
97 %. This is similar to that reported previously (Petrović 
et al. 2013), which showed an incorporation efficiency of 
98 % for 5FW, and 95 % for 5HW and 5MeW. These data 
indicate that the incorporation system and the incorporation 
method are efficient and widely applicable.
Although NisBTC was expressed in advance, the accu-
mulated NisBTC performed the modification and trans-
portation correctly. The mutants I4W and V32W variants 
showed a one time less dehydration extent, which is prob-
ably because the serines besides the tryptophan residues 
escaped dehydration. All mutants were cut well by NisP, 
which indicates that the mutation (especially I1W) and the 
analogues did not affect the activity of NisP.
Incorporating non-canonical amino acids into peptides 
is a method to introduce new properties into the peptides. 
The 5HW incorporation significantly changed the column 
desorption properties of nisin, which is probably because 
of the additional hydrogen bonding properties and an 
increased polarity of this analogue compared to Trp.
The first two rings of nisin can bind to lipid II by form-
ing a pyrophosphate cage (Hsu et al. 2004). Against L. lac-
tis, the I1W mutant showed only a twofold reduced activ-
ity, which is similar to the activity tested previously against 
M. flavus (Kuipers et al. 1995; Demel et al. 1996; Breukink 
et al. 1998). This indicates that the first Ile is not crucial 
for the binding. 5FW labelled I1W showed the same activ-
ity, which means that the fluorine group did not change the 
property of the peptide significantly. 5HW labelled mutant 
I1W showed two times lower activity than I1W, which 
means that the hydroxyl is detrimental for the binding 
activity of nisin. Ile4 plays an important role in the pyroph-
osphate cage formation (Hsu et al. 2004). However, 5FW 
labelled mutant I4W only modestly reduced the activity, 
which is probably because a pyrophosphate cage is formed 
by the backbone amides of Ile4 and the side chain of resi-
due 4 does not significantly affect the binding. The MIC of 
I4W was not tested, but from the case of I1W and I1-5FW, 
the fluorine group would not change the activity signifi-
cantly. Mutation of Met17 into Trp or 5HW decreased the 
activity dramatically (32 times). This suggests that the new 
bulkier side chain of residue 17 is too bulky to go into the 
membrane; therefore the binding efficiency and the pore 
formation activity of the peptide was reduced. In the pre-
vious study, the M17W mutant of nisin Z displayed only 
two times reduced activity against M. flavus and eight 
times reduced activity against S. thermophilus (Demel et al. 
1996; Breukink et al. 1998), and the difference in activity 
might be related to the different indicator strains.
Nisin cannot be detected by UV at 280 nm because 
it contains no tryptophan or tyrosine residues. Introduc-
ing tryptophan or tryptophan analogues into nisin has the 
advantage of the UV detection being used during purifica-
tion and for quantification. Furthermore, there are various 
kinds of tryptophan analogues, which show different prop-
erties and functions. If they could be incorporated into nisin, 
the activity and other characters of nisin might be improved.
Taken together, this research has opened the door to 
efficiently incorporate tryptophan analogues into nisin. 
The expression platform used here, Trp auxotroph PA1002 
coexpressing lacTrpRS, is the most versatile Trp analogue 
incorporation system known, able to incorporate a large 
variety of Trp analogues as well as an amino acid contain-
ing the azulene moiety. Most of these analogues are com-
mercially available or can be readily synthesized. In future 
studies, more residue positions should be targeted and the 
antimicrobial activity of the generated nisin peptides inves-
tigated. These structure function studies will also provide 
valuable insight into the mechanism of action of nisin.
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